Board of Directors
Dr Brett Haumann
Brett Haumann is a seasoned pharmaceutical physician and senior executive with more than 25 years of experience in the pharmaceutical and biotechnology sector, having served as a non-executive director on a number of private and public boards in Europe and the US. He was formerly Head of the R&D Committee on the Board of Aimmune Therapeutics (2018-2020), which launched Palforzia® for the treatment of peanut allergy prior to its acquisition by Nestlé in 2020.
Dr. Haumann is a physician with an MBBCh degree from the University of Witwatersrand in South Africa and an MBA degree with distinction from Open University in the UK.
Mr Aizaz Syed
Aizaz Syed is a Portfolio and Investment Manager at Tenmile, the dedicated health technology investment business owned by Tattarang. He has extensive experience in early-stage investing, strategy, financial and commercial advisory and has sat on a number of boards for early-stage businesses commercialising innovative technologies. He was previously an Investment Director at early-stage investment firm Nightingale Partners prior to which he worked in Corporate and Investment Banking at Bank of America Merrill Lynch.
Aizaz holds a Bachelor of Commerce and a Bachelor of Laws from Australian National University and is admitted as a solicitor to the NSW Supreme Court.
Dr Chris Smith
Chris Smith is an Investment Manager at Brandon Capital Partners with over 15 years’ scientific and commercial experience in the pharmaceutical industry. He was formerly a Business Development Manager with CSL Ltd and has experience with both in and out-licensing of therapeutic drugs and R&D enabling platforms.
Dr Smith received his PhD at the Walter and Eliza Hall Institute, Australia and his MBA (specialising in innovation and entrepreneurship) from the University of Cambridge, U.K.
Mr Thomas Ulmer
Thomas Ulmer is a Senior Financial Executive with almost 20 years of experience directing all financial matters. He was formerly the Chief Financial Officer of Immatics N.V., where he was instrumental in leading the company to its NASDAQ listing. Previous leadership positions include Chief Financial Officer of Allergopharma and VP Business Planning & Analysis for the Merck Group.
Mr Ulmer received his MBA from University of Giessen, Germany and is a Fellow member of CPA Australia.